INTRODUCTIONNewer generation drug‐eluting stents (DES) have been developed. These stents feature thinner struts and biocompatible or biodegradable polymers that release eluted drug at lower dosages, resulting in a remarkable reduction in the risk of death, stent thrombosis (ST), or myocardial infarction (MI), as well as a lower risk of repeat revascularization . The biodegradable‐polymer sirolimus‐eluting stent (BP‐SES) (Tivoli, Essen Technology, Beijing, China) represents a further iteration of DES technology by combining a biodegradable polymer with cobalt–chromium (CoCr) platform. In the prior reported one‐year result of I‐LOVE‐IT 2 (Evaluate Safety and Effectiveness of the Tivoli DES and the Firebird DES for Treatment of Coronary Revascularization) trial, the BP‐SES was noninferior to the durable‐polymer sirolimus‐eluting stent (DP‐SES) (Firebird2, Microport Medical, Shanghai, China) in the primary composite safety and efficacy endpoint of target‐lesion failure (TLF) at 12 months . Nevertheless, long‐term data comparing the BP‐DES versus the DP‐DES are scarce. The purpose of this study was to report the long‐term clinical outcomes of patients included in the I‐LOVE‐IT 2 trial over a 3‐year follow‐up period.MATERIALS AND METHODSStudy Design and PatientsThe I‐LOVE‐IT 2 trial (NCT01681381) was a prospective, multicenter, randomized, assessor‐blinded, noninferiority study comparing the BP‐SES with the DP‐SES. Between October 2012 and
Catheterization and Cardiovascular Interventions – Wiley
Published: Jan 15, 2018
Keywords: ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud